BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34945856)

  • 1. Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma.
    Petronilho S; Sequeira JP; Paulino S; Lopes P; Lisboa S; Chacim S; Lobo J; Teixeira M; Jerónimo C; Henrique R
    J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2/Bcl-2 Coexpression Predicts Worse Survival in Diffuse Large B-cell Lymphomas and Demonstrates Poor Efficacy to Rituximab in Localized Lesions.
    Deng Y; Chen X; Huang C; Chen G; Chen F; Lu J; Shi X; He C; Zeng Z; Qiu Y; Chen J; Lin R; Chen Y; Chen J
    J Cancer; 2019; 10(9):2006-2017. PubMed ID: 31205561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
    Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
    Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
    Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
    Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of H3K27me3 and EZH2 in Predicting the Therapeutic Efficacy of Diffuse Large B-Cell Lymphoma].
    Deng YJ; Chen G; Zhu WF; Chen XH; Hong HL; Huang LM; Shi X; Chen JM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):159-165. PubMed ID: 29397836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicentre retrospective study of primary breast diffuse large B-cell and high-grade B-cell lymphoma treatment strategies and survival.
    Zhang T; Zhao H; Cui Z; Xu H; Liu X; Wu Y; Li Y; Sun S; Wang P; Wang Y; Shi X
    Hematology; 2020 Dec; 25(1):203-210. PubMed ID: 32476626
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.
    Guo S; Bai Q; Rohr J; Wang Y; Liu Y; Zeng K; Yu K; Zhang X; Wang Z
    APMIS; 2016 Dec; 124(12):1054-1062. PubMed ID: 27807891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
    Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
    Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.
    Neves Filho EH; Hirth CG; Frederico IA; Burbano RM; Carneiro T; Rabenhorst SH
    APMIS; 2020 Apr; 128(4):308-315. PubMed ID: 31991488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin in standard RCHOP chemotherapy for elderly diffuse large B-Cell lymphoma: a retrospective study in China.
    Zhou D; Li L; Bao C; Zhu J; Zhu L; Yang X; Zheng Y; Zhou M; Luo X; Xie W; Ye X
    Int J Clin Exp Med; 2015; 8(12):22497-502. PubMed ID: 26885233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma.
    Oñate-Ocaña LF; Ponce-Martínez M; Taja-Chayeb L; Gutiérrez-Hernández O; Avilés-Salas A; Cantú-de-León D; Dueñas-González A; Candelaria-Hernández M
    Rev Invest Clin; 2021 Nov; 73(6):362-370. PubMed ID: 34044429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?
    Chung C
    Blood Lymphat Cancer; 2022; 12():99-106. PubMed ID: 35959380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to improve RCHOP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of 21 randomized controlled trials.
    Intzes S; Symeonidou M; Zagoridis K; Pentidou A; Bezirgianidou Z; Papoutselis M; Misidou C; Roumpakis C; Spanoudaki A; Liapis K; Spanoudakis E
    Ann Hematol; 2024 May; 103(5):1623-1633. PubMed ID: 38191715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics and diffuse large B-Cell lymphoma.
    Niroula R; Butera J
    R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
    Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
    J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic nutritional index as a predictor of prognosis in patients with diffuse large B cell lymphoma.
    Periša V; Zibar L; Knezović A; Periša I; Sinčić-Petričević J; Aurer I
    Wien Klin Wochenschr; 2017 Jun; 129(11-12):411-419. PubMed ID: 27637206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of key genes associated with R‑CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B‑cell lymphoma.
    Liu R; Chen Z; Wang S; Zhao G; Gu Y; Han Q; Chen B
    Mol Med Rep; 2019 Oct; 20(4):3679-3690. PubMed ID: 31485671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
    Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
    J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement.
    Kang BW; Moon JH; Chae YS; Lee SJ; Kim JG; Kim YK; Lee JJ; Yang DH; Kim HJ; Kim JY; Do YR; Park KU; Song HS; Kwon KY; Kim MK; Lee KH; Hyun MS; Ryoo HM; Bae SH; Kim H; Sohn SK
    Cancer Res Treat; 2013 Jun; 45(2):112-7. PubMed ID: 23864844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.